Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALPPL2/ALPG-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALPPL2/ALPG ECD-Fc Fusion Protein (HEK293, >95% purity, Endotoxin <1EU/µg, Sequence Verified) | View ALPPL2/ALPG Products |
| Gene Delivery | ALPPL2/ALPG Full-Length ORF Lentivirus (GPI-Anchor Intact, for stable cell lines) | View ALPPL2/ALPG Products |
| Benchmark Ab | Anti-ALPPL2/ALPG (Clinical Sequence Reference, recombinant positive control) | View ALPPL2/ALPG Products |
| Validator | ALPPL2/ALPG siRNA Set (for knockdown verification and specificity confirmation) | View ALPPL2/ALPG Products |
| Related Target A (Counter-Screen) | ALPP (Placental Alkaline Phosphatase, >95% homology, crucial for off-target assessment) | View ALPP Products |
| Related Target B (Counter-Screen) | ALPL (Tissue-Nonspecific AP, liver/bone/kidney, for toxicity cross-reactivity) | View ALPL Products |
| Related Target C (Counter-Screen) | ALPI (Intestinal Alkaline Phosphatase, essential for GI toxicity evaluation) | View ALPI Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Specificity (ALPPL2 vs ALPP vs ALPI vs ALPL) | Homolog panel (ALPPL2, ALPP, ALPL, ALPI) expressed in parallel HEK293; Mass Spec verified; >95% purity for epitope mapping |
| Cynomolgus Preclinical Cross-Reactivity | Human/Cynomolgus ALPPL2 ortholog comparison proteins available; Theoretical MW confirmed |
| Internalization Efficiency (ADC Payload Delivery) | High-purity ECD-Fc for binding; Lentivirus-transduced stable cell lines for pH-dependent trafficking assays |
| False Positive Binding (GPI-anchor artifacts) | Validated siRNA included for target-specificity confirmation in flow cytometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay development |
Live ALPPL2/ALPG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALPPL2/ALPG therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs), CAR-T cell therapies, and bispecific modalities. As an oncofetal antigen with high expression in mesothelioma, gastric, pancreatic, and ovarian cancers but minimal healthy adult tissue expression, ALPPL2 presents a highly attractive therapeutic window. First-generation therapies (e.g., SOT102 from SOTIO Biotech, SGN-ALPV from Seagen/Pfizer) target a broad spectrum of alkaline phosphatase family members but face challenges from cross-reactivity with ALPP (placenta) and ALPI (intestine), leading to on-target off-tumor toxicities. The next wave of R&D is focusing on highly specific epitope engineering to achieve ultra-selective binding to ALPPL2, along with isoform-specific counter-screening and sophisticated internalization assays to maximize efficacy and safety.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | SOTIO Biotech (SOT102), Seagen/Pfizer (SGN-ALPV), Emerging Biotechs | Gastric Cancer, Testicular Germ Cell Tumors, Mesothelioma, Pancreatic Cancer | Internalization Assay: High-purity ECD-Fc for binding, lentivirus-stable lines for pH-dependent trafficking |
| Monospecific mAb | Preclinical Programs | Solid Tumors (GI, ovarian) | Isoform Selectivity Panel: ALPPL2 vs ALPP vs ALPL vs ALPI proteins for binding confirmation |
| Bispecific / T-cell Engager | Early Discovery | Immunotherapy Combinations, Refractory Solid Tumors | Heterodimer Validation: Cross-reactive Abs & high-purity targets for specificity |
| CAR-T / Cell Therapy | Various Biotechs & Academic Consortia (e.g., UCSF) | Refractory Solid Tumors (mesothelioma, ovarian) | Flow Cytometry Binding: Lentivirus for stable cell lines expressing native GPI-anchored ALPPL2 |
| Targeted Radionuclide Therapy | Academic Consortia | Ovarian, Gastric | Selectivity Assay: Homolog panel proteins for off-tissue binding assessment |